All News
Count Your Telangiectasias (5.29.2026)
Dr. Jack Cush reviews the news, journal articles and missed quiz questions.
Read Article
Safety of Biologics and Novel Agents
Dr. Jack Cush reviews safety of biologics and novel agents.
Read Article
Quiz Talk (5.22.2026)
Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.
Read Article
Immune-Mediated Inflammatory Diseases Following Uveitis
A Korean insurance claims data study showed children and adolescents diagnosed with uveitis have a 7-fold increased risk of developing an immune-mediated inflammatory disorder (IMID).
Read Article
Influential Rheumatoid Factors (5.8.2026)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com
Read Article
Breaking the Rules: Dual-Advanced Combinations in Rheumatology
For decades, the standard of care in rheumatology has been combination therapy - pairing methotrexate (MTX) with an advanced biologic or synthetic agent to achieve optimal outcomes.
Read Article
22% of psoriasis patients developed #PsAover 17 years of follow-up. PsA occurred in 44% of TNFi-treated vs only 9–14% of those on IL-23i or IL-12/23i. Time to discuss "preventive biologics" in PsO? Prospective controlled trials are needed Abstr#072 @RheumNow #EULAR2026
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
In a 17-year real-world psoriasis cohort, patients on IL-17i had 75% lower odds and IL-23i patients had 84% lower odds of developing #PsA vs TNF inhibitors. Is biologic class selection a PsA interception strategy? Prospective controlled trials are needed Abstr#072 @RheumNow https://t.co/jpdZjGK7VV
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Small interventional synovial biopsy precision medicine study
CD117 high pts n=15 = better response to IL17i or IL23i inhibition vs. TNFi w/
-DAPSA -13.5, -12.8 vs. -7.5 respectively
Higher BL levels of tissue inflammation in Responders vs. NR
More robust study design needed https://t.co/7jNff6lUJ6
Aurelie Najm AurelieRheumo ( View Tweet)
#OP085 from Sweden adds more real-world data to the JAKi safety discussion at #EULAR2026. In >26000 RA treatment initiations, JAKis were associated with higher VTE risk vs TNFi (HR 1.89), with similar findings persisting in 2021-2024 data. @RheumNow https://t.co/YRjPNZ8mmo
Mrinalini Dey DrMiniDey ( View Tweet)
💉 Add tirzepatide to biologics in obese #PsA?
#POS0050: Yes! Propensity score-matched study (n=93):
better PROs, HAQ & PASI at 6 months
#EULAR2026 @RheumNow
@vincevenerito https://t.co/rrhNKZByjc
Nelly ZIADE 🍀 Nellziade ( View Tweet)
True or False: After successfully treating herpes zoster, it is considered safe to restart anti-TNF therapy without a significant risk of recurrence. See if you got it right in this week's RheumIQ quiz at https://t.co/DX0qT1iNF2 https://t.co/pGggdVPhmh
Dr. John Cush RheumNow ( View Tweet)
RHEUM SURVEY> Per 2024 EULAR Guidelines, an active RA pt on MTX who fails a 1st TNFi, should next change to ?
Dr. John Cush RheumNow ( View Tweet)
The safe/right choice is H. Zoster. You never fully eradicate invasive fungal or NTM infections. HBV is too risky to again use TNFi again. After H.zoster is Rx,there is evidence its safe to restart TNFi without risk of recurrence. Vagal N. Stim is the mechanistically same as
Dr. John Cush RheumNow ( View Tweet)
RHEUM Survey: After treating which infection can you safely resume anti-TNF therapy?
Dr. John Cush RheumNow ( View Tweet)
RHEUM Survey: After treating which infection can you safely resume anti-TNF therapy?
Dr. John Cush RheumNow ( View Tweet)
In this week's RheumIQ quiz: An RA patient has a current or new cancer. With which cancer should you avoid/stop the use of a TNF inhibitor? See if you got it right at https://t.co/DTabBEfjj9 https://t.co/tVYUEjAPy3
Dr. John Cush RheumNow ( View Tweet)
Another IL-17A inhibitor (Vunakizumab) for active Ankylosing Spondylitis
Vunakizumab, a novel anti–interleukin (IL) 17A monoclonal antibody, was studied in patients with active radiographic axial spondyloarthritis [r-axSpA] and found to be effective and tolerable. https://t.co/y0mw7tRWbs
Dr. John Cush RheumNow ( View Tweet)
Meet the RheumNow #EULAR2026 Reporting Team
Delivering real-time insights from the forefront of rheumatology:
🩺 Dr. Antoni Chan (@synovialjoints)
🩺 Dr. Mrinalini Dey (@DrMiniDey)
🩺 Dr. Jiha Lee (@JihaRheum)
🩺 Dr. Aurelie Najm (@AurelieRheumo)
🩺 Dr. Janet Pope https://t.co/zpIeGWpL6P
Dr. John Cush RheumNow ( View Tweet)
Taiwan, real-world study 267 RA new DMARD starts w/ tofacitinib (145) or TNFi (122). Post adjustments; no significant difference in Efficacy, AEs, Serious AE (20 v 21%), MACE (0 v 0.8%), CA (2% vs 0.8%), deaths (1.4% vs 3.3), SIE (13% vs 8.2%) or H zoster (12% v 3%) https://t.co/XLsdfKyeGx
Dr. John Cush RheumNow ( View Tweet)
